Parallel synthesis of "Click" chalcones as antitubulin agents

Medicinal Chemistry

Volumn 9, Issue 4, 2013, Pages 510-516

  Utsintong, Maleeruk ^a   Massarotti, Alberto ^b   Caldarelli, Antonio ^b   Theeramunkong, Sewan ^b  

^a UNIVERSITY OF PHAYAO   (Thailand)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Antitubulinic agent; Cancer; Chalcone analogs; Click chemistry; Cytotoxicity; Tubulin

Indexed keywords

CHALCONE DERIVATIVE; TUBULIN MODULATOR;

ARTICLE; CLICK CHEMISTRY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG INHIBITION; HUMAN; HUMAN CELL; IC 50; MICROTUBULE ASSEMBLY; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

CELL LINE, TUMOR; CHALCONES; CLICK CHEMISTRY; HUMANS; TUBULIN; TUBULIN MODULATORS;

EID: 84877974352     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/1573406411309040004     Document Type: Article

References (26)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics. 2010 CA Cancer J. Clin., 2010, 60(5), 277-300.
2. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, 2004, 4(4), 253-265.
3. Perez, E.A. Microtubule inhibitors: Differentiating tubulininhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol. Cancer Ther., 2009, 8(8), 2086-2095.
4. Jordan, A., Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med. Res. Rev., 1998, 18(4), 259-296.
5. Attard, G.; Greystoke, A.; Kaye, S.; De Bono, J. Update on tubulinbinding agents. Pathol. Biol. (Paris), 2006, 54(2), 72-84.
6. Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A. Medicinal chemistry of combretastatin A4: present and future directions. J. Med. Chem., 2006, 49(11), 3033-3044.
7. Tozer, G. M.; Kanthou, C.; Baguley, B.C. Disrupting tumour blood vessels. Nat. Rev. Cancer, 2005, 5(6), 423-435.
8. Hsieh, H. P.; Liou, J. P.; Mahindroo, N. Pharmaceutical design of antimitotic agents based on combretastatins. Curr. Pharm. Des. 2005, 11(13), 1655-1677.
9. Mason, R. P.; Zhao, D.; Liu, L.; Trawick, M. L.; Pinney, K. G. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. Integr. Biol. (Camb), 2011, 3(4), 375-387.
10. Ducki, S.; Forrest, R.; Hadfield, J. A.; Kendall, A.; Lawrence, N. J.; McGown, A. T.; Rennison, D. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett., 1998, 8(9), 1051-1056.
11. Lawrence, N.J.; McGown, A.T.; Ducki, S.; Hadfield, J.A. The interaction of chalcones with tubulin. Anticancer Drug Des., 2000, 15(2), 135-141.
12. Ducki, S.; Mackenzie, G.; Greedy, B.; Armitage, S.; Chabert, J. F.; Bennett, E.; Nettles, J.; Snyder, J. P.; Lawrence, N. J. Combretastatin- like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones. Bioorg. Med. Chem., 2009, 17(22), 7711-7722.
13. Pettit, G. R. Progress in the discovery of biosynthetic anticancer drugs. J. Nat. Prod., 1996, 59(8), 812-821.
14. Rubinstein, L. V.; Shoemaker, R. H.; Paull, K. D.; Simon, R. M.; Tosini, S.; Skehan, P.; Scudiero, D.A.; Monks, A.; Boyd, M. R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst., 1990, 82(13), 1113-1118.
15. Lawrence, N. J.; McGown, A. T. The chemistry and biology of antimitotic chalcones and related enone systems. Curr. Pharm. Des., 2005, 11(13), 1679-1693.
16. Chen, J.; Wang, Z.; Li, C. M.; Lu, Y.; Vaddady, P. K.; Meibohm, B.; Dalton, J. T.; Miller, D. D.; Li, W. Discovery of novel 2-aryl-4- benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. J. Med. Chem., 2010, 53(20), 7414- 7427.
17. Dalton, J. T. Compounds for treatment of cancer, USA, 2011.
18. Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Click Chemistry: Diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. Engl., 2001, 40(11), 2004-2021.
19. Hein, J.E.; Fokin, V.V. Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and beyond: new reactivity of copper(I) acetylides. Chem. Soc. Rev., 2010, 39(4), 1302-1315.
20. Meldal, M.; Tornoe, C.W. Cu-catalyzed azide-alkyne cycloaddition. Chem. Rev., 2008, 108(8), 2952-3015.
21. Tron, G. C.; Pirali, T.; Billington, R. A.; Canonico, P. L.; Sorba, G.; Genazzani, A. A. Click chemistry reactions in medicinal chemistry: applications of the 1, 3-dipolar cycloaddition between azides and alkynes. Med. Res. Rev., 2008, 28(2), 278-308.
22. Liang, L.; Astruc, D. The copper(I)-catalyzed alkyne-azide cycloaddition (CuACC) "click" reaction and its applications: an overview. Coordin. Chem. Rev., 2011, 255, 2933-2945.
23. Mesenzani, O.; Massarotti, A.; Giustiniano, M.; Pirali, T.; Bevilacqua, V.; Caldarelli, A.; Canonico, P.; Sorba, G.; Novellino, E.; Genazzani, A. A.; Tron, G. C. Replacement of the double bond of antitubulin chalcones with triazoles and tetrazoles: Synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2011, 21(2), 764- 768.
24. Massarotti, A.; Coluccia, A.; Silvestri, R.; Sorba, G.; Brancale, A. The tubulin colchicine domain: a molecular modeling perspective. ChemMedChem, 2012, 7(1), 33-42.
25. Chassaing, S.; Kueny-Stotz, M.; Isorez, G.; Brouillard, R. Rapid preparation of 3-Deoxyanthocyanidins and novel dicationic derivatives: New insight into an old procedure. Eur. J. Org. Chem., 2007, 2007(15), 2438-2448.
26. Imperio, D.; Pirali, T.; Galli, U.; Pagliai, F.; Cafici, L.; Canonico, P. L.; Sorba, G.; Genazzani, A. A.; Tron, G. C. Replacement of the lactone moiety on podophyllotoxin and steganacin analogs with a 1, 5-disubstituted 1, 2, 3-triazole via ruthenium-catalyzed click chemistry. Bioorg. Med. Chem., 2007, 15(21), 6748-6757.